



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boyle et al.

Serial No.: 09/405,032

Filed: September 24, 1999

For: Osteoprotegerin

Docket No.: A-378CIP2C2

ATTORNEY'S STATEMENT PURSUANT TO 37 CFR § 1.821

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

I hereby state that the substitute paper copy and the substitute computer readable form (CRF) of the "Sequence Listing" submitted herewith for the above-mentioned patent application are the same.

The sequence listing submitted herewith contains no new matter.

No fees are believed due; however, the Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,


Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.: 34,458
Phone: (805) 447-2425
Date: September 28, 2001

Please send all future correspondence to:

U.S. Patent Operations/ RBW
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE

Express Mail mail labeling number: EL360690028US

Date of Deposit: September 28, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Box Response, Assistant Commissioner for Patents, Washington, D.C. 20231.

Lynne Buchsbaum
Printed Name


Signature